DALLMEDICA ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Bankruptcy risk for industry  2.2% 2.2% 2.2% 2.2% 2.2%  
Bankruptcy risk  16.0% 19.4% 18.1% 14.3% 19.5%  
Credit score (0-100)  12 6 7 14 5  
Credit rating  BB B B BB B  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4

Net sales  0 0 0 0 0  
Gross profit  -58.6 -85.4 -95.2 -104 -10.1  
EBITDA  -58.6 -85.4 -95.2 -104 -10.1  
EBIT  -58.6 -85.4 -95.2 -104 -10.1  
Pre-tax profit (PTP)  -58.6 -87.1 -95.2 -103.8 -10.1  
Net earnings  -45.7 -68.3 -74.3 -81.0 -7.9  
Pre-tax profit without non-rec. items  -58.6 -87.1 -95.2 -104 -10.1  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  486 417 343 262 254  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  493 426 352 271 262  

Net Debt  -2.2 -6.3 -5.3 -4.4 -4.9  
 
See the entire balance sheet

Volume 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -58.6 -85.4 -95.2 -104 -10.1  
Gross profit growth  34.2% -45.7% -11.5% -9.1% 90.3%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  493 426 352 271 262  
Balance sheet change%  -8.5% -13.6% -17.3% -23.2% -3.4%  
Added value  -58.6 -85.4 -95.2 -103.8 -10.1  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -11.4% -18.6% -24.5% -33.3% -3.8%  
ROI %  -11.5% -18.9% -25.0% -34.3% -3.9%  
ROE %  -9.0% -15.1% -19.5% -26.7% -3.0%  

Solidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Equity ratio %  98.5% 98.0% 97.4% 96.9% 97.2%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  3.8% 7.3% 5.6% 4.3% 49.0%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Quick Ratio  68.5 49.7 38.8 32.0 36.3  
Current Ratio  68.5 49.7 38.8 32.0 36.3  
Cash and cash equivalent  2.2 6.3 5.3 4.4 4.9  

Capital use efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  485.8 417.5 343.2 262.2 254.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/4
2020
2021/4
2021
2022/4
2022
2023/4
2023
2024/4
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0